A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up

Gynecologic Oncology

Volumn 103, Issue 1, 2006, Pages 315-320

  Sallinen, Hanna ^a,b   Anttila, Maarit ^a,b   Narvainen, Johanna ^a   Ordén, Maija Riitta ^b   Ropponen, Kirsi ^b   Kosma, Veli Matti ^b   Heinonen, Seppo ^b   Yla Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Animal model; Carcinoma; Human; MRI; Ovary; Ultrasound

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MODEL; CANCER SURVIVAL; CELL STRAIN; CELL STRAIN SKOV 3M; CYSTADENOCARCINOMA; DIAGNOSTIC IMAGING; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; REPRODUCIBILITY; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT;

ANIMALS; CELL LINEAGE; DISEASE MODELS, ANIMAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33748560189     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.03.030     Document Type: Article

References (42)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics, 2004. CA Cancer J Clin 54 1 (2004) 8-29
2. Runnebaum I.B., and Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 127 2 (2001) 73-79
3. Averette H.E., Hoskins W., Nguyen H.N., Boike G., Flessa H.C., Chmiel J.S., et al. National survey of ovarian carcinoma: I. A patient care evaluation study of the American College of Surgeons. Cancer 71 4 Suppl. (1993) 1629-1638
4. FIGO (International Federation of Gynecology and Obstetrics) annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2003; 83 (Suppl 1): ix-xxii, 1-229; ix-229.
5. Fogh J., Fogh J.M., and Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59 1 (1977) 221-226
6. Kullander S., Rausing A., and Trope C. Human ovarian tumours heterotransplanted to "nude" mice. Acta Obstet Gynecol Scand 57 2 (1978) 149-159
7. Molpus K.L., Koelliker D., Atkins L., Kato D.T., Buczek-Thomas J., Fuller Jr. A.F., et al. Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. Int J Cancer 68 5 (1996) 588-595
8. Hamilton T.C., Young R.C., Louie K.G., Behrens B.C., McKoy W.M., Grotzinger K.R., et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 44 11 (1984) 5286-5290
9. Fu X., and Hoffman R.M. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res 13 2 (1993) 283-286
10. Massazza G., Tomasoni A., Lucchini V., Allavena P., Erba E., Colombo N., et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer 44 3 (1989) 494-500
11. Ward B.G., Wallace K., Shepherd J.H., and Balkwill F.R. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res 47 10 (1987) 2662-2667
12. Elkas J.C., Baldwin R.L., Pegram M., Tseng Y., Slamon D., and Karlan B.Y. A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol 87 2 (2002) 200-206
13. Xu Y., Silver D.F., Yang N.P., Oflazoglu E., Hempling R.E., Piver M.S., et al. Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol 72 2 (1999) 161-170
14. Schumacher U., Adam E., Horny H.P., and Dietl J. Transplantation of a human ovarian cystadenocarcinoma into severe combined immunodeficient (SCID) mice-formation of metastases without significant alteration of the tumour cell phenotype. Int J Exp Pathol 77 5 (1996) 219-227
15. Sekiya S., Endoh N., Kikuchi Y., Katoh T., Matsuura A., Iwasawa H., et al. In vivo and in vitro studies of experimental ovarian adenocarcinoma in rats. Cancer Res 39 3 (1979) 1108-1112
16. Rose G.S., Tocco L.M., Granger G.A., DiSaia P.J., Hamilton T.C., Santin A.D., et al. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol 175 3 Pt 1 (1996) 593-599
17. Rodriguez-Burford C., Barnes M.N., Berry W., Partridge E.E., and Grizzle W.E. Immunohistochemical expression of molecular markers in an avian model: a potential model for preclinical evaluation of agents for ovarian cancer chemoprevention. Gynecol Oncol 81 3 (2001) 373-379
18. Bogden A.E. The subrenal capsule assay (SRCA) and its predictive value in oncology. Ann Chir Gynaecol Suppl 199 (1985) 12-27
19. Griffin T.W., Bogden A.E., Reich S.D., Antonelli D., Hunter R.E., Ward A., et al. Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy. Cancer 52 12 (1983) 2185-2192
20. Maenpaa J., Kangas L., and Gronroos M. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I. Obstet Gynecol 66 5 (1985) 708-713
21. Fiebig H.H., Schuchhardt C., Henss H., Fiedler L., and Lohr G.W. Comparison of tumor response in nude mice and in the patients. Behring Inst Mitt 74 (1984) 343-352
22. Lee C.H., Xue H., Sutcliffe M., Gout P.W., Huntsman D.G., Miller D.M., et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 96 1 (2005) 48-55
23. Stratton J.A., Kucera P.R., Rettenmaier M.A., Dobashi K., Micha J.P., Braly P.S., et al. Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin. Gynecol Oncol 25 3 (1986) 302-310
24. Dinulescu D.M., Ince T.A., Quade B.J., Shafer S.A., Crowley D., and Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11 1 (2005) 63-70
25. Orsulic S., Li Y., Soslow R.A., Vitale-Cross L.A., Gutkind J.S., and Varmus H.E. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1 1 (2002) 53-62
26. Connolly D.C., Bao R., Nikitin A.Y., Stephens K.C., Poole T.W., Hua X., et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 63 6 (2003) 1389-1397
27. Flesken-Nikitin A., Choi K.C., Eng J.P., Shmidt E.N., and Nikitin A.Y. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 63 13 (2003) 3459-3463
28. Yla-Herttuala S., Rosenfeld M.E., Parthasarathy S., Glass C.K., Sigal E., Witztum J.L., et al. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci U S A 87 18 (1990) 6959-6963
29. Haapasalo H., Pesonen E., and Collan Y. Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms. Pathol Res Pract 185 5 (1989) 551-554
30. Tavassoli D. In: Tavassoli D. (Ed). Tumors of the breast and female genital organs (2003), Pathology & Genetics, Lyon
31. Mujoo K., Maneval D.C., Anderson S.C., and Gutterman J.U. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 12 8 (1996) 1617-1623
32. Shaw T.J., Senterman M.K., Dawson K., Crane C.A., and Vanderhyden B.C. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10 6 (2004) 1032-1042
33. Yu D., Wolf J.K., Scanlon M., Price J.E., and Hung M.C. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53 4 (1993) 891-898
34. Yanagawa R., Furukawa Y., Tsunoda T., Kitahara O., Kameyama M., Murata K., et al. Genome-wide screening of genes showing altered expression in liver metastases of human colorectal cancers by cDNA microarray. Neoplasia 3 5 (2001) 395-401
35. Hao X., Sun B., Hu L., Lahdesmaki H., Dunmire V., Feng Y., et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 100 6 (2004) 1110-1122
36. St Croix B., and Kerbel R.S. Cell adhesion and drug resistance in cancer. Curr Opin Oncol 9 6 (1997) 549-556
37. Agarwal R., and Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3 7 (2003) 502-516
38. Pulkkanen K.J., Parkkinen J.J., Kettunen M.I., Kauppinen R.A., Lappalainen M., Ala-Opas M.Y., et al. Characterization of a new animal model for human renal cell carcinoma. In Vivo 14 3 (2000) 393-400
39. He Z., Evelhoch J.L., Mohammad R.M., Adsay N.V., Pettit G.R., Vaitkevicius V.K., et al. Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer. Pancreas 21 1 (2000) 69-76
40. Abdulkadir S.A., Qu Z., Garabedian E., Song S.K., Peters T.J., Svaren J., et al. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 7 1 (2001) 101-107
41. Vertrees R.A., Deyo D.J., Quast M., Lightfoot K.M., Boor P.J., and Zwischenberger J.B. Development of a human to murine orthotopic xenotransplanted lung cancer model. J Invest Surg 13 6 (2000) 349-358
42. Beauregard D.A., Pedley R.B., Hill S.A., and Brindle K.M. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 15 2 (2002) 99-105